A detailed history of Wolverine Trading, LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 11,465 shares of HRTX stock, worth $18,114. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,465
Previous 17,900 35.95%
Holding current value
$18,114
Previous $62,000 64.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.73 - $3.67 $19,834 - $42,076
11,465 New
11,465 $22,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.06 $1,997 - $3,574
-1,168 Reduced 6.99%
15,553 $43,000
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $9,029 - $30,432
16,721 New
16,721 $28,000
Q1 2021

May 14, 2021

BUY
$14.49 - $20.72 $335,124 - $479,212
23,128 New
23,128 $354,000
Q3 2020

Nov 13, 2020

SELL
$13.67 - $17.77 $211,802 - $275,328
-15,494 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$10.89 - $21.47 $13,427 - $26,472
-1,233 Reduced 7.37%
15,494 $221,000
Q4 2019

Feb 12, 2020

BUY
$17.42 - $26.61 $18,291 - $27,940
1,050 Added 6.7%
16,727 $395,000
Q3 2019

Nov 14, 2019

SELL
$16.36 - $21.39 $339,355 - $443,692
-20,743 Reduced 56.95%
15,677 $307,000
Q2 2019

Aug 20, 2019

SELL
$16.93 - $26.22 $118,628 - $183,723
-7,007 Reduced 16.14%
36,420 $677,000
Q1 2019

May 15, 2019

BUY
$23.15 - $28.34 $486,543 - $595,621
21,017 Added 93.78%
43,427 $1.06 Million
Q4 2018

Feb 14, 2019

BUY
$22.03 - $32.01 $308,331 - $448,011
13,996 Added 166.34%
22,410 $532,000
Q3 2018

Nov 14, 2018

SELL
$30.0 - $40.85 $1.07 Million - $1.46 Million
-35,736 Reduced 80.94%
8,414 $266,000
Q1 2018

May 15, 2018

BUY
$18.43 - $28.8 $813,684 - $1.27 Million
44,150 New
44,150 $1.22 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $188M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.